Loading…
PRPO
Precipio, Inc.
NASDAQ· Healthcare· Diagnostics & Research· CUSIP 74019L602
$28.85-1.50%Price as of Aug 29, 18:40 UTC · updated once a day, after the close
Key metrics
- Market cap
- $51.65M
- P/E
- —
- Forward P/E
- 74.0x
- P/B
- 3.5x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.62
- ROE
- -8.98%
- Profit margin
- -4.47%
- Revenue growth
- +24.20%
- Beta
- 1.29
- 52-week high
- $33.63
- 52-week low
- $14.28
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -49.9% over 5Y.
today you would have $419.33▼ -58.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 9 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $22.98 | $5.54 | $6.50 | $11.02 | $31.60 | $41.40 | $41.00 | $46.20 | $360.00 | |
| P/S | 3.3x | 1.7x | 0.4x | 0.6x | 1.3x | 4.1x | 5.1x | 4.4x | 3.3x | 11.6x |
| P/B | 1.5x | 2.8x |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$4.74
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ELOXEloxx Pharmaceuticals, Inc. | $15.07 | 4.7x | 1.3x | — | — | $51.79M |
| TILInstil Bio, Inc. | $7.58 | — | 0.5x | — | -25.33% | $51.41M |
| TCRXTScan Therapeutics, Inc. | $0.75 | — | 0.5x | — | -95.81% | $51.07M |
| MDAISpectral AI, Inc. | $1.57 |
About the company
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
- 61
- New Haven, United States
Company description provided by Yahoo Finance.